A compound selected from Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: the solid/dash line ------ indicates a single or double bond; X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 2 or N; where none, one, or two of X 1, X 2, and X 3 are N; Y 1 and Y 2 are independently selected from CH and N; Y 3 is C or N; Y 4 is CR 6, N or NH; where one or two of Y 1, Y 2, Y 3 and Y 4 are N; R 1, R 2 and R 3 are independently selected from H, F, Cl, -NH 2, -NHCH 3, -N(CH 3) 2,-OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl optionally substituted with F, Cl, CN, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH; R 4 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxyoxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 5 is selected from -CH 3, -CH 2 CH 3, -CH 2 OH, -CH 2 F, -CHF 2, -CF 3, -CN, and-CH 2 CH 2 OH; or two R 5 groups form a 3-, 4-, 5-, or 6-membered carbocyclic or heterocyclic ring; or an R 5 group and an R 8 group form a 3-, 4-, 5-, or 6-membered carbocyclic or heterocyclic ring; n is 0, 1, 2, 3, or 4; R 6 is selected from H, Cl, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -CH 2 F, -CR 2, -CF 3,-NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH; R 7 is selected from the structures: where the wavy line indicates the site of attachment; R 8 is selected from H, -CH 3, -S 2 CH 3, cyclopropyl, azetidin-3-yl, oxetan-3-yl, and morpholin-4-yl; Z is CR 9 or N; wherein R 9 is selected from H, F, Cl, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH. the solid/dash line ------ indicates a single or double bond; X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 2 or N; where none, one, or two of X 1, X 2, and X 3 are N; Y 1 and Y 2 are independently selected from CH and N; Y 3 is C or N; Y 4 is CR 6, N or NH; where one or two of Y 1, Y 2, Y 3 and Y 4 are N; R 1, R 2 and R 3 are independently selected from H, F, Cl, -NH 2, -NHCH 3, -N(CH 3) 2,-OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl optionally substituted with F, Cl, CN, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH; R 4 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxyoxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 5 is selected from -CH 3, -CH 2 CH 3, -CH 2 OH, -CH 2 F, -CHF 2, -CF 3, -CN, and-CH 2 CH 2 OH; or two R 5 groups form a 3-, 4-, 5-, or 6-membered carbocyclic or heterocyclic ring; or an R 5 group and an R 8 group form a 3-, 4-, 5-, or 6-membered carbocyclic or heterocyclic ring; n is 0, 1, 2, 3, or 4; R 6 is selected from H, Cl, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -CH 2 F, -CR 2, -CF 3,-NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH; R 7 is selected from the structures: where the wavy line indicates the site of attachment; R 8 is selected from H, -CH 3, -S 2 CH 3, cyclopropyl, azetidin-3-yl, oxetan-3-yl, and morpholin-4-yl; Z is CR 9 or N; wherein R 9 is selected from H, F, Cl, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH. R 8 is selected from H, -CH 3, -S 2 CH 3, cyclopropyl, azetidin-3-yl, oxetan-3-yl, and morpholin-4-yl; Z is CR 9 or N; wherein R 9 is selected from H, F, Cl, -CH 3, -CH 2 CH 3, -CH 2 CH 2 OH, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, and -OCH 2 CH 2 OH.